Multiple mRNAs in inflammatory and survival pathways

The term "Multiple mRNAs in inflammatory and survival pathways" does not refer to a single canonical therapeutic target but rather describes a broad strategy or a collection of targets involved in complex disease processes. In the context of drug development, this typically refers to the use of multi-targeted RNA-based therapies, such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), designed to silence several genes at once. These genes often encode cytokines, growth factors, or anti-apoptotic proteins that drive chronic inflammation and tumor cell resistance. By targeting multiple transcripts, these therapies aim to overcome the redundancy of biological networks that often leads to drug resistance in cancer and inflammatory disorders. However, because this is a descriptive category rather than a specific molecular entity, it is considered an incorrect or non-specific target name for structured pharmacological databases.

Other names

Inflammatory and survival pathway transcriptsMulti-mRNA target set

Antisense oligonucleotides or RNA interference (RNAi) molecules can be designed to bind to and promote the degradation of multiple specific mRNA transcripts simultaneously to modulate complex biological pathways.